carrying the telomerase Tert gene in two independent mouse models of aplastic anemia 1 0 owing to short telomeres (Trf1 and Tert-deficient mice). We find that a high dose of 1 1 AAV9-Tert targets the bone marrow compartment including hematopoietic stem cells.
Introduction

3
Aplastic anemia is a potentially life-threatening, rare and heterogeneous disorder 4 of the blood in which the bone marrow cannot produce sufficient new blood cells due to 5 a marked reduction of immature hematopoietic stem and progenitor cells (HSPC) 1, 2 . The 6 main disease manifestations are pancytopenia and marrow hypoplasia, which can 7 emerge at any stage of life but are more frequent in young individuals (age 10-25 years) 8 and in the elderly (>60 years) 3 . Aplastic anemia can be acquired or inherited. The 9 acquired type is often of idiopathic origin, involves autoimmune processes but can also presence of short telomeres in subpopulations of peripheral blood cells (in particular 1 5 neutrophiles and less prominent in lymphocytes) 6 , even in the absence of mutations in 1 6 the telomere maintenance machinery.
7
Telomeres, the termini of vertebrate chromosomes, are specialized nucleoprotein six protein complex (TRF1, TRF2, TIN2, RAP1, TPP1 and POT1) known as shelterin 7, 8 .
0
Telomeres are essential for chromosome integrity by preventing telomere fusions and telomerase, which can add telomeric sequences onto telomeres de novo. Because also show an accelerated rate of shortening in patients with aplastic anemia compared 1 1 to healthy individuals, most likely owing to a higher than normal number of cell divisions 1 2 in the aplastic anemia cases 13 .
3
Accelerated telomere shortening due to defects in telomerase or other telomere 1 4 maintenance genes prematurely limits the proliferation potential of cells, including stem 1 5 cells, leading to decreased tissue renewal capacity 9, 14 . Highly proliferative tissues such 1 6 as the hematopoietic system are particularly vulnerable to defects in telomere 1 7 maintenance genes, leading to severe disorders such as aplastic anemia 15 . As an 1 8 example, the telomeropathy Dyskeratosis congenita (DKC) has been linked to 1 9 mutations in 11 genes, which encode components of the telomerase complex (TERT, 2 0 TERC, DKC1, NOP10, NHP2) or of the telomere capping complex shelterin (TIN2).
1
Other genes altered in DKC encode for accessory proteins important for telomerase 2 2 assembly and trafficking (CTC1, ACD7 (alias TPP1) and TCAB1) or for telomere 2 3
For personal use only. These findings suggest that telomerase activation could be a good therapeutic 9 strategy to treat those forms of aplastic anemia associated with a limited blood forming 1 0 capacity owing to the presence of very short telomeres. We have previously developed To test the efficacy of this strategy in the treatment of aplastic anemia, we first 1 5 used a mouse model of aplastic anemia generated by us in which we depleted the 1 6 TRF1 shelterin protein specifically in the bone marrow, leading to a bone marrow 1 7 phenotype that recapitulates the main pathological findings of human aplastic anemia 1 8 patients, including extreme telomere shortening 19, 20 . In particular, partial depletion of the 1 9 Trf1 gene specifically in bone marrow causes severe telomere uncapping and provokes 2 0 a persistent DNA damage response at telomeres, which in turn leads to a fast clearance anemia, as well as in patients owing to mutations in telomere maintenance genes.
5
Interestingly, this mouse model allows adjustment of the rate of telomere shortening by 6 modulating the frequency of Trf1 deletion-mediated HSPC depletion, thus controlling the 7 onset of bone marrow aplasia and pancytopenia 19, 20 .
8
As an additional model to mimic the presence of very short telomeres specifically 9 in the bone marrow, we transplanted irradiated wild-type mice with bone marrow from 1 0 late (third) generation (G3) telomerase-deficient Tert knock-out mice, which have short 1 1 telomeres owing to telomerase deficiency during three mouse generations.
2
Here, we tested telomerase activation by using gene therapy AAV vectors in both 1 3 mouse models of aplastic anemia produced by short telomeres. Our results show that 1 4 telomerase treatment is sufficient to attenuate telomere attrition with time as well as 1 5 HSPC depletion, thus significantly preventing death by bone marrow failure.
6
For personal use only. Bone marrow samples (sternum or tibia bone) were fixed in 4% PFA and paraffin 1 0 embedded after decalcification. 5μm tissue sections were stained with Hematoxylin-
Eosin. Immunohistochemistry was performed on deparaffinized sections. After antigen EGFP positive cells were counted in a semi-automated way using ImageJ software. For sorting of HSPCs, whole bone marrow cells were extracted from the long MethoCult media (both StemCell Technologies) following the manufacturer's protocol.
0
All experiments were performed in duplicates and the number of colonies counted after 1 1 12 days incubation at 37°C. Blood counts 1 4 Peripheral blood was drawn from the facial vein (~50μl) and collected into anti- veterinary hematology analyzer. Quantitative real-time PCR and Western blots 1 9 Total RNA from whole bone marrow extracts or FACS sorted bone marrow cells 2 0 was isolated using Qiagen's RNeasy mini kit according to the manufacturer.
1
Quantitative real-time PCR was performed using an ABI PRISM 7700 or QuantStudio 6 2 2
Flex (both Applied Biosystems). Primers sequences for Tert and reference genes Act1 QFISH on paraffin-embedded tissue sections was performed as described 27 .
7
Confocal images were acquired as stacks every 0.5μm for a total of 1.5μm using a 8 Leica SP5-MP confocal microscope and maximum projections were done with the LAS-
9
AF software. Telomere signal intensity was quantified in at least 6 images per mouse 1 0
using Definiens software with a specific script allowing for individual spot background
HT-QFISH on peripheral blood leukocytes was done using 120-150μl of blood as . Confocal images were captured using the OPERA (Perkin Elmer) High-
Content Screening system. TL values were analysed using individual telomere spots sample were converted into kilobase using L5178-R and L5178-S cells as calibration analysed in duplicate.
Real time PCR-based measurement of relative telomere length was done on 2 0
genomic DNA isolated from whole bone marrow samples following a protocol previously joints, which showed the highest AAV9-transduction (Fig. 1A,B) . We then injected wild- the AAV9 serotype, we found a stronger induction of Tert in organs such as heart and
liver, which are preferential AAV9 targets ( Supplementary Fig. 1A -C) 32 . We then
studied Tert mRNA expression specifically in the blood-forming compartments of the Tert treated mice compared to mice treated with the empty vector ( Fig. 1F,G Fig. 2 ). Given the increased Tert expression in HSPCs, we next
addressed whether this affected their proliferation/colony forming potential. To this end,
we performed a colony forming cell assay (MethoCult). We observed a significantly compared to those treated with the empty vector (Fig. 1H ).
4
In summary, intravenous injection of AAV9 vectors administered at a high dose can target Tert to hematopoietic cells, including HSPCs. We next tested whether treatment with AAV9-Tert was effective in increasing
survival upon induction of lethal aplastic anemia owing to critically short telomeres. First, (Supplementary Fig. 3 ). Thus, . One week after the last pI:pC injection, mice were treated with either AAV9-
Tert or AAV9-empty vectors ( Fig. 2A) . Mouse survival was monitored for 100 days treatment significantly increased survival, as we found 87% of mice still alive at 100
days after virus administration in the AAV9-Tert treated group compared to only 55% of 1 7 mice alive in the empty vector-treated group (Fig. 2B) . In particular, while only 4 out of treated with the empty vector (Fig. 2C) . In both groups, aplastic anemia was determined 2 1
as the cause of death in those mice that showed a drastic drop in platelet counts and in 2 2
haemoglobin levels at the time of death (Fig. 2D,E) , and that presented with severe 2 3 bone marrow hypo-and aplasia after post-mortem histopathologic analysis of bone 1 marrow sections (Fig. 2F) . Interestingly, among those mice that died from aplastic 2 anemia, we observed a tendency to show a milder bone marrow aplasia phenotype in 3 the AAV9-Tert treated group compared with the AAV9-empty treated group as indicated 4 by higher bone marrow cellularity in the AAV9-Tert treated group (Fig. 2F) .
5
Quantification of the bone marrow cellularity confirmed a drastic decrease of cellularity 6 in aplastic anemia mice compared to the wild-type control mice. Importantly, the 7 decrease in cellularity was significantly attenuated in the AAV9-Tert treated cohort 8 compared with the AAV9-empty treated group (Fig. 2G,H) . Our results suggest that reduces the mortality of these mice by aplastic anemia. Because aplastic anemia in our mouse model is caused by extreme telomere longitudinal study to follow telomere length in peripheral blood (PBMCs) over time using . We observed a further drop in telomere length in 3 those mice treated with AAV9-empty vector, when comparing timepoint 4 with timepoint 4 2 in this mouse cohort (Fig. 3A,B) . Importantly, during the same period of time, mice 5 treated with AAV9-Tert showed a net increase in average telomere of 10kb when 6 comparing timepoint 4 with timepoint 2 (Fig. 3A,B) . Indeed, throughout the course of ( Fig. 3C) . These findings indicate that AAV9-Tert treatment is sufficient to stop and longer telomeres in the bone marrow compared with mice treated with the empty vector 1 7
( Fig. 3D-F) . We confirmed the AAV9-Tert mediated telomere elongation on independent ( Supplementary Fig. 4A ). Furthermore, in line with our hypothesis that aplastic anemia 2 0
is the consequence of drastically shortened telomeres, mice treated with AAV9-empty 2 1 that developed aplastic anemia had significantly shorter telomeres than mice that were provoked by short telomeres, we used an additional mouse model for modelling short 1 1 telomere length in the hematopoietic system, in this case owing to telomerase including the bone marrow 22 (Fig. 4A) . First, we confirmed shorter telomeres in the G1 and G3 Tert knock-out bone marrow donors compared to the wild-type bone marrow
donors by performing HT-QFISH analysis on peripheral blood mononuclear cells. In third generation (G3) having an average telomere length of ~25kb compared to ~40kb in 2 0 the wild-type controls (Fig. 4B) . One month after transplantation of irradiated wild-type were divided in two groups and then treated with either AAV9-Tert or AAV9-empty gene (Fig. 4C) . Upon mouse sacrifice, Tert treated mice had 6 significantly increased haemoglobin levels and higher erythrocyte and platelets counts 7 compared with mice treated with the empty vector ( Fig. 4D-F) . The same trend was 8 observed for leukocyte counts, which again were higher in AAV9-Tert treated mice 9 compared with the AAV9-empty group although the trend did not reach statistical
significance (P=0.09) (Fig. 4G) . Finally, to analyse the mechanism by which Tert gene 1 1 therapy improved survival and blood counts in these mice, we followed longitudinally mice treated with the AAV9-empty vector suffered a slight telomere shortening of -1 8
1.76Kb (Fig. 5A,B) . These findings were also confirmed by telomere QFISH analysis on 1 9 bone marrow sections at 5 months after virus administration. In particular, we found 2 0 significantly longer telomeres in the bone marrow of Tert treated mice compared to mice 2 1 treated with the empty vector (Fig. 5C,D) . In summary, these results indicate a single treatment with the AAV9-Tert vector 1 in mice with previously shortened telomeres in the bone marrow owing to telomerase 2 deficiency, is sufficient to increase telomere length in the bone marrow and in blood.
3
Telomerase gene therapy also improved blood counts and mouse survival. The rational for this study was based on our previous finding showing that 8 systemic AAV9-Tert gene therapy in wild-type mice was sufficient to delay different age-9 related diseases and to significantly increase mouse life span by delaying telomere Tert delivery via AAV9 may hold potential to treat aplastic anemia triggered or telomerase mutations in the so-called telomeropathies or telomere syndromes, as well 2 0 as in some acquired cases of aplastic anemia [37] [38] [39] .
1
To demonstrate this, we first confirmed that a high dose (3.5*10^12 vg/mouse) of 2 2 AAV9-EGFP reporter vector injected intravenously, was able to transduce the bone suggesting that telomerase expression may increase the stem cell reserve. cells from these mice after telomerase treatment. We confirmed these findings by 1 4 generating a second mouse model of aplastic anemia produced by short telomeres, in 1 5 this case owing to telomerase deficiency. In particular, we generated mice with Tert In summary, here we provide proof of concept for a therapeutic effect of with telomerase expression imposes specific safety concerns. In this regard, it is 2 0 important to point out that in a previous study more than 1-year follow up of wild-type C.B. wrote the paper. 
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Herrera extracted at 4 different time points: (1) before pI:pC treatment, (2) after 5 weeks of pI:pC 2 0 treatment (before AAV9 injection), (3) 2 months and (4) 4 months after AAV9 injection. design. G3 tert -/-mice with short telomeres were generated by consecutive crosses of
Tert deficient mice. Bone marrow from these G3 mice was isolated and transplanted Representative images of bone marrow sections from AAV-Tert and AAV9-empty 
